IO Frontiers World 2019

Why Phacilitate

Phacilitate is a specialist in the organisation of exclusive events for leaders from the pharma and biotech communities. Our philosophy is simple - to deliver the ultimate in strategic knowledge exchange and networking through flawless, personalised service.

Our team is focused on just a handful of events each year – our Cell & Gene Therapy World and Immuno-Oncology Frontiers (Miami, January); Cell & Gene Therapy Europe and Immuno-Oncology Frontiers (Berlin, September); and our Big Data in Precision Medicine (Washington, DC, October). This level of specialisation means that we have closer links with, and spend more time listening to, the industry we serve than any other conference organiser, aided by the input of our Advisory Boards.

Before a Phacilitate programme is written, we spend at least six weeks conducting intensive market research with potential delegates, sponsors and exhibitors. On the basis of the results of this research, we then work closely with our Advisory Boards to devise agendas that as closely as possible meet all the learning needs of senior industry executives. And we are also listening hard to all types of attendee in order to be able to constantly improve the format of our events. This runs right from agenda structures, which we are constantly seeking to make more and more interactive, through to our online partnering system.

If you would like to find out more about the way we deliver value to our clients, or would like to make any suggestions for new topic areas or formats you would like to see us address, please contact

Michael Adeniya, Event Manager on +44 (0)20 7384 7971 |

Be part of a Phacilitate event



  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy